Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer
Elisa Agostinetto, Daniel Eiger, Kevin Punie, et al.
Current Oncology Reports (2021) Vol. 23, Iss. 5
Closed Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Systemic therapy for early-stage breast cancer: learning from the past to build the future
Elisa Agostinetto, Joseph Gligorov, Martine Piccart
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 12, pp. 763-774
Open Access | Times Cited: 81
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
R. Gerosa, Rita De Sanctis, Flavia Jacobs, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104324-104324
Open Access | Times Cited: 19
Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer
Xinyun Qiu, Yan Qu, Beibei Guo, et al.
Journal of Controlled Release (2021) Vol. 341, pp. 498-510
Closed Access | Times Cited: 77
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer
Elisa Agostinetto, Agnese Losurdo, Guilherme Nader Marta, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 6, pp. 567-591
Open Access | Times Cited: 58
The emerging role of noncoding RNAs in the PI3K/AKT/mTOR signalling pathway in breast cancer
Mohammed H. Abu-Alghayth, Farhan R. Khan, Tareg M. Belali, et al.
Pathology - Research and Practice (2024) Vol. 255, pp. 155180-155180
Closed Access | Times Cited: 8
Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer
Rui Sha, Xinrui Dong, Shanshan Yan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
VISTA: A Promising Target for Cancer Immunotherapy?
Marco Tagliamento, Elisa Agostinetto, Roberto Borea, et al.
ImmunoTargets and Therapy (2021) Vol. Volume 10, pp. 185-200
Open Access | Times Cited: 46
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
Elisa Agostinetto, Filippo Montemurro, Fabio Puglisi, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2136-2136
Open Access | Times Cited: 37
A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer
Xiangdi Meng, Yuanyuan Cai, Xiaolong Chang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 17
Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer
Flavia Jacobs, Elisa Agostinetto, Chiara Miggiano, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2933-2933
Open Access | Times Cited: 16
FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters
Mengjiao Li, Tatsunori Nishimura, Yasuto Takeuchi, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 22
Open Access | Times Cited: 15
Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells
Ming Lei, Yun‐Long Zhang, Feng‐Ying Huang, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 14
Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets
Tatiana Vilela, Sofia Valente, Jorge Correia, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189144-189144
Open Access | Times Cited: 5
Contrastive Learning for Omics-guided Whole-slide Visual Embedding Representation
Suwan Yu, Yooeun Kim, Hyun-Seok Kim, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer
Runtian Wang, Kun Xu, Fangyan Gao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 2, pp. 188590-188590
Closed Access | Times Cited: 28
Anthracyclines in the treatment of patients with early breast cancer
Valentina Guarneri, Evandro de Azambuja
ESMO Open (2022) Vol. 7, Iss. 3, pp. 100461-100461
Open Access | Times Cited: 17
Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK
Qinhang Wu, Xuelin Ma, Zhuolin Jin, et al.
Journal of Ethnopharmacology (2023) Vol. 315, pp. 116644-116644
Closed Access | Times Cited: 10
Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1
Venhar Çınar, Zühal Hamurcu, Ahsen Güler, et al.
Breast Cancer (2022) Vol. 29, Iss. 6, pp. 1106-1120
Open Access | Times Cited: 13
Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study
Ebru Karcı, Ahmet Bılıcı, Buket Bayram, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3389-3389
Open Access | Times Cited: 2
Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis
Rafael Caparica, Marco Bruzzone, Elisa Agostinetto, et al.
The Breast (2021) Vol. 59, pp. 183-192
Open Access | Times Cited: 17
The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting
Natsuki Furukawa, Vered Stearns, Cesar A. Santa‐Maria, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 12, pp. 1041-1056
Open Access | Times Cited: 11
Research Status of Systemic Adjuvant Therapy for Early Breast Cancer
Wenyu Hu, Dongdong Xu, Nanlin Li
Cancer Control (2023) Vol. 30
Open Access | Times Cited: 6
ADRB2 is a potential protective gene in breast cancer by regulating tumor immune microenvironment
Wei Xiang, Liang Chen, Aiming Yang, et al.
Translational Cancer Research (2021) Vol. 10, Iss. 12, pp. 5280-5294
Open Access | Times Cited: 13
Ceramide Synthase 6 Mediates Triple-Negative Breast Cancer Response to Chemotherapy Through RhoA- and EGFR-Mediated Signaling Pathways
Hui Chen, Bin He, Ke Feng
Journal of Breast Cancer (2022) Vol. 25, Iss. 6, pp. 500-500
Open Access | Times Cited: 9
Nanodrug regulates ROS homeostasisviaenhancing fatty acid oxidation and inhibiting autophagy to overcome tumor drug resistance
Haiyang Wang, Minzhao Lin, Gengjia Chen, et al.
Biomaterials Science (2023) Vol. 11, Iss. 21, pp. 7179-7187
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top